|
1
|
Ciriello G, Gatza ML, Beck AH, Wilkerson
MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et
al: Comprehensive molecular portraits of invasive lobular breast
cancer. Cell. 163:506–519. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kohler BA, Sherman RL, Howlader N, Jemal
A, Ryerson AB, Henry KA, Boscoe FP, Cronin KA, Lake A, Noone AM, et
al: Annual report to the nation on the status of cancer, 1975–2011,
featuring incidence of breast cancer subtypes by race/ethnicity,
poverty, and state. J Natl Cancer Inst. 107:djv0482015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sorlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perou CM, Sorlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boyle P: Triple-negative breast cancer:
Epidemiological considerations and recommendations. Ann Oncol. 23
(Suppl 6):vi7–vi12. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee HW, Jang KS, Choi HJ, Jo A, Cheong JH
and Chun KH: Celastrol inhibits gastric cancer growth by induction
of apoptosis and autophagy. BMB Rep. 47:697–702. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rajendran P, Li F, Shanmugam MK, Kannaiyan
R, Goh JN, Wong KF, Wang W, Khin E, Tergaonkar V, Kumar AP, et al:
Celastrol suppresses growth and induces apoptosis of human
hepatocellular carcinoma through the modulation of STAT3/JAK2
signaling cascade in vitro and in vivo. Cancer Prev Res (Phila).
5:631–643. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin L, Sun Y, Wang D, Zheng S, Zhang J and
Zheng C: Celastrol ameliorates ulcerative colitis-related
colorectal cancer in mice via suppressing inflammatory responses
and epithelial-mesenchymal transition. Front Pharmacol.
6:3202015.PubMed/NCBI
|
|
10
|
Zhao J, Sun Y, Shi P, Dong JN, Zuo LG,
Wang HG, Gong JF, Li Y, Gu LL, Li N, et al: Celastrol ameliorates
experimental colitis in IL-10 deficient mice via the up-regulation
of autophagy. Int Immunopharmacol. 26:221–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Broide DH: Molecular and cellular
mechanisms of allergic disease. J Allergy Clin Immunol. 108((2
Suppl)): S65–S71. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dranoff G: Cytokines in cancer
pathogenesis and cancer therapy. Nat Rev Cancer. 4:11–22. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jeon M, Han J, Nam SJ, Lee JE and Kim S:
Elevated IL-1β expression induces invasiveness of triple negative
breast cancer cells and is suppressed by zerumbone. Chem Biol
Interact. 258:126–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shao N, Lu Z, Zhang Y, Wang M, Li W, Hu Z,
Wang S and Lin Y: Interleukin-8 upregulates integrin β3 expression
and promotes estrogen receptor-negative breast cancer cell invasion
by activating the PI3K/Akt/NF-κB pathway. Cancer Lett. 364:165–172.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Han J, Bae SY, Oh SJ, Lee J, Lee JH, Lee
HC, Lee SK, Kil WH, Kim SW, Nam SJ, et al: Zerumbone suppresses
IL-1β-induced cell migration and invasion by inhibiting IL-8 and
MMP-3 expression in human triple-negative breast cancer cells.
Phytother Res. 28:1654–1660. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lewis AM, Varghese S, Xu H and Alexander
HR: Interleukin-1 and cancer progression: The emerging role of
interleukin-1 receptor antagonist as a novel therapeutic agent in
cancer treatment. J Transl Med. 4:482006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tulotta C, Lefley DV, Freeman K, Gregory
WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington
AR, Liu X, et al: Endogenous production of IL-1Β by breast cancer
cells drives metastasis and colonization of the bone
microenvironment. Clin Cancer Res. 25:2769–2782. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Todorović-Rakovic N and Milovanović J:
Interleukin-8 in breast cancer progression. J Interferon Cytokine
Res. 33:563–570. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim S, Lee J, Jeon M, Lee JE and Nam SJ:
MEK-dependent IL-8 induction regulates the invasiveness of
triple-negative breast cancer cells. Tumour Biol. 37:4991–4999.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim S, You D, Jeong Y, Yoon SY, Kim SA,
Kim SW, Nam SJ and Lee JE: WNT5A augments cell invasiveness by
inducing CXCL8 in HER2-positive breast cancer cells. Cytokine.
135:1552132020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim S, You D, Jeong Y, Yu J, Kim SW, Nam
SJ and Lee JE: Berberine down-regulates IL-8 expression through
inhibition of the EGFR/MEK/ERK pathway in triple-negative breast
cancer cells. Phytomedicine. 50:43–49. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dmitrieva OS, Shilovskiy IP, Khaitov MR
and Grivennikov SI: Interleukins 1 and 6 as main mediators of
inflammation and cancer. Biochemistry (Mosc). 81:80–90. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pantschenko AG, Pushkar I, Anderson KH,
Wang Y, Miller LJ, Kurtzman SH, Barrows G and Kreutzer DL: The
interleukin-1 family of cytokines and receptors in human breast
cancer: Implications for tumor progression. Int J Oncol.
23:269–284. 2003.PubMed/NCBI
|
|
25
|
Miller LJ, Kurtzman SH, Anderson K, Wang
Y, Stankus M, Renna M, Lindquist R, Barrows G and Kreutzer DL:
Interleukin-1 family expression in human breast cancer:
Interleukin-1 receptor antagonist. Cancer Invest. 18:293–302. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Elaraj DM, Weinreich DM, Varghese S,
Puhlmann M, Hewitt SM, Carroll NM, Feldman ED, Turner EM and
Alexander HR: The role of interleukin 1 in growth and metastasis of
human cancer xenografts. Clin Cancer Res. 12:1088–1096. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A,
Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, et al:
Expression of interleukin-1beta in human breast carcinoma. Cancer.
80:421–434. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma L, Lan F, Zheng Z, Xie F, Wang L, Liu
W, Han J, Zheng F, Xie Y and Huang Q: Epidermal growth factor (EGF)
and interleukin (IL)-1β synergistically promote ERK1/2-mediated
invasive breast ductal cancer cell migration and invasion. Mol
Cancer. 11:792012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yoshimura H, Nakahama K, Safronova O,
Tanaka N, Muneta T and Morita I: Transforming growth factor-beta
stimulates IL-1beta-induced monocyte chemoattractant protein-1
expression in human synovial cells via the ERK/AP-1 pathway.
Inflamm Res. 55:543–549. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dinarello CA: Immunological and
inflammatory functions of the interleukin-1 family. Annu Rev
Immunol. 27:519–550. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hou Z, Falcone DJ, Subbaramaiah K and
Dannenberg AJ: Macrophages induce COX-2 expression in breast cancer
cells: Role of IL-1β autoamplification. Carcinogenesis. 32:695–702.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Collins TS, Lee LF and Ting JP: Paclitaxel
up-regulates interleukin-8 synthesis in human lung carcinoma
through an NF-kappaB- and AP-1-dependent mechanism. Cancer Immunol
Immunother. 49:78–84. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Westermarck J and Kahari VM: Regulation of
matrix metalloproteinase expression in tumor invasion. FASEB J.
13:781–792. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jackson BC, Nebert DW and Vasiliou V:
Update of human and mouse matrix metalloproteinase families. Hum
Genomics. 4:194–201. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kannaiyan R, Hay HS, Rajendran P, Li F,
Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, et
al: Celastrol inhibits proliferation and induces chemosensitization
through down-regulation of NF-κB and STAT3 regulated gene products
in multiple myeloma cells. Br J Pharmacol. 164:1506–1521. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee JH, Won YS, Park KH, Lee MK, Tachibana
H, Yamada K and Seo KI: Celastrol inhibits growth and induces
apoptotic cell death in melanoma cells via the activation
ROS-dependent mitochondrial pathway and the suppression of PI3K/AKT
signaling. Apoptosis. 17:1275–1286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mou H, Zheng Y, Zhao P, Bao H, Fang W and
Xu N: Celastrol induces apoptosis in non-small-cell lung cancer
A549 cells through activation of mitochondria- and
Fas/FasL-mediated pathways. Toxicol In Vitro. 25:1027–1032. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li H, Yuan Y, Zhang Y, He Q, Xu R, Ge F
and Wu C: Celastrol inhibits IL-1β-induced inflammation in orbital
fibroblasts through the suppression of NF-κB activity. Mol Med Rep.
14:2799–2806. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang J, Zhou K, Zhang X, Zhou Y, Li Z and
Shang F: Celastrol ameliorates inflammation in human retinal
pigment epithelial cells by suppressing NF-κB signaling. J Ocul
Pharmacol Ther. 35:116–123. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim Y, Kang H, Jang SW and Ko J: Celastrol
inhibits breast cancer cell invasion via suppression of
NF-kB-mediated matrix metalloproteinase-9 expression. Cell Physiol
Biochem. 28:175–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Park S, Jung HH, Park YH, Ahn JS and Im
YH: ERK/MAPK pathways play critical roles in EGFR ligands-induced
MMP1 expression. Biochem Biophys Res Commun. 407:680–686. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hashimoto K, Otero M, Imagawa K, de Andrés
MC, Coico JM, Roach HI, Oreffo RO, Marcu KB and Goldring MB:
Regulated transcription of human matrix metalloproteinase 13
(MMP13) and interleukin-1β (IL-1Β) genes in chondrocytes depends on
methylation of specific proximal promoter CpG sites. J Biol Chem.
288:10061–10072. 2013. View Article : Google Scholar : PubMed/NCBI
|
